|
WO2011112679A1
|
|
Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same
|
|
US2007196482A1
|
|
Sustained release torsemide dosage forms
|
|
ZA200902096B
|
|
Robust sustained release formulations
|
|
CN101578095A
|
|
Robust sustained release formulations
|
|
US2008085305A1
|
|
Robust sustained release formulations of oxymorphone
|
|
KR20090065543A
|
|
Robust sustained release formulations of oxymorphone and methods of use thereof
|
|
CA2652981A1
|
|
Robust sustained release formulations
|
|
AU2006349472A1
|
|
Robust sustained release formulations of oxymorphone and methods of use thereof
|
|
US2008085303A1
|
|
Robust sustained release formulations of oxymorphone and methods of use thereof
|
|
US2008085304A1
|
|
Robust sustained release formulations
|
|
US2007212414A1
|
|
Ethanol-resistant sustained release formulations
|
|
US2006228413A1
|
|
Controlled release venlafaxine formulations
|
|
AP200603650A0
|
|
Sustained release torsemide dosage forms
|
|
KR20060070565A
|
|
Delayed release dosage forms
|
|
AU2004201845A1
|
|
Sustained Release Heterodisperse Hydrogel Systems - Amorphous Drugs
|
|
AU2003246326A1
|
|
Sustained Release Matrix Systems for Highly Soluble Drugs
|
|
CA2481091A1
|
|
Sustained release metoprolol formulations
|
|
MXPA03008293A
|
|
Chronotherapeutic dosage forms.
|
|
IL155102D0
|
|
Delivery system for multi-pharmaceutical active materials at various release rates
|
|
US6726930B1
|
|
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
